Neuroblastoma - Market Insights, Epidemiology and Market Forecast-2028

January 2019 | 100 pages | ID: NE107AE0ACAEN
DelveInsight

Abstracts

This report can be delivered to the clients within 7-10 Business Days

DelveInsight’s ‘Neuroblastoma - Market Insights, Epidemiology and Market Forecast-2028’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Neuroblastoma in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Neuroblastoma from 2016 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan

Study Period: 2016-2028

Neuroblastoma - Disease Understanding and Treatment Algorithm
The DelveInsight Neuroblastoma market report gives the thorough understanding of Neuroblastoma by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Neuroblastoma in the US, Europe, and Japan.
Neuroblastoma Epidemiology
The Neuroblastoma epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [total incident patient population and incident cases by risk groups (Low risk, intermediate risk and high risk)] scenario in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2028.

According to DelveInsight, total incident cases of Neuroblastoma in 7 major markets is found to be about 1530 in 2016.
Neuroblastoma Drug Chapters
This segment of Neuroblastoma report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Given the nature of the cancer and multimodal treatment options available for Neuroblstoma, various systemic therapies were administered. The therapies which are used to treat Neuroblastoma are Chemotherapies (Chemotherapy agents from: Cyclophosphamide, etoposide, doxorubicin, carboplatin, topotecan, cisplatin, vincristine, melphalan, busulfan, etc), Retinoid therapy (Isotretinoin) and Immunotherapies (Qarziba and Unituxin).
Detailed chapter for upcoming therapies Naxitamab (Y-mAbs Therapeutics Inc.), Omburtamab (Y-mAbs Therapeutics Inc.), Bevacizumab, Irinotecan and Temozolomide (Genentech, Inc), CPP-1X (Cancer Prevention Pharmaceuticals), MNX-100 (MetronomX) etc., have been covered in the report.
Neuroblastoma Market Outlook
The Neuroblastoma market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Neuroblastoma in 7MM was found to be USD 733.58 million in 2016, and is expected to increase at a CAGR of XX% from 2016-2028.
Neuroblastoma Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Neuroblastoma Report Insights

• Patient Population
• Therapeutic Approaches
• Pipeline Analysis
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Neuroblastoma Report Key Strengths

• 10 Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition

Neuroblastoma Report Assessment

• Current Treatment Practices
• Unmet Needs
• Detailed Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

KEY BENEFITS

• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Neuroblastoma market
• Organize sales and marketing efforts by identifying the best opportunities for Neuroblastoma market
• To understand the future market competition in the Neuroblastoma market.

Contents

1. KEY INSIGHTS

2. NEUROBLASTOMA MARKET OVERVIEW AT A GLANCE

3. MARKET SHARE (%) DISTRIBUTION OF NEUROBLASTOMA IN 2016

4. MARKET SHARE (%) DISTRIBUTION OF NEUROBLASTOMA IN 2028

5. DISEASE BACKGROUND AND OVERVIEW

6. INTRODUCTION

6.1. STAGES OF NEUROBLASTOMA
  6.1.1. International Neuroblastoma Staging System (INSS)
  6.1.2. International Neuroblastoma Risk Group Staging System (INRGSS)
6.2. NEUROBLASTOMA RISK GROUPS
  6.2.1. Children’s Oncology Group (COG) Risk Group Classification
  6.2.2. International Neuroblastoma Risk Group (INRG) classification
  6.2.3. COG and INRG Classifications
  6.2.4. Current COG Neuroblastoma Risk Stratification
6.3. SIGNS AND SYMPTOMS
6.4. ETIOLOGY
6.5. PATHOGENESIS
6.6. THERAPEUTIC TARGETS FOR NEUROBLASTOMA
6.7. DIAGNOSIS

7. EPIDEMIOLOGY AND PATIENT POPULATION

8. KEY FINDINGS

9. POPULATION AND FORECAST PARAMETERS

10. 7MM TOTAL INCIDENT PATIENT POPULATION OF NEUROBLASTOMA

11. COUNTRY WISE-EPIDEMIOLOGY OF NEUROBLASTOMA

11.1. United States
  11.1.1. Total Incident Patient Population of Neuroblastoma in the United States
  11.1.2. Distribution of Incident cases by Risk Groups – Neuroblastoma
11.2. EU5 Countries
11.3. Germany
  11.3.1. Total Incident Patient Population of Neuroblastoma in Germany
  11.3.2. Distribution of Incident cases by Risk Groups – Neuroblastoma
11.4. France
  11.4.1. Total Incident Patient Population of Neuroblastoma in France
  11.4.2. Distribution of Incident cases by Risk Groups – Neuroblastoma
11.5. United Kingdom
  11.5.1. Total Incident Patient Population of Neuroblastoma in the United Kingdom
  11.5.2. Distribution of Incident cases by Risk Groups – Neuroblastoma
11.6. Spain
  11.6.1. Total Incident Patient Population of Neuroblastoma in Spain
  11.6.2. Distribution of Incident cases by Risk Groups – Neuroblastoma
11.7. Italy
  11.7.1. Total Incident Patient Population of Neuroblastoma in Italy
  11.7.2. Distribution of Incident cases by Risk Groups – Neuroblastoma
11.8. Japan
  11.8.1. Total Incident Patient Population of Neuroblastoma in Japan
  11.8.2. Distribution of Incident cases by Risk Groups – Neuroblastoma

12. CURRENT TREATMENT AND MEDICAL PRACTICES

12.1. American Cancer Society Recommendations
12.2. American Society Of Clinical Oncology Recommendations
12.3. Cancer Research United Kingdom Treatment Recommendations
12.4. Gesellschaft Fьr Pдdiatrische Onkologie Und Hдmatologie (Gpoh) Recommendations
12.5. Siop-podc Adapted Risk Stratification And Treatment Guidelines Recommendations For Neuroblastoma
12.6. Top 6 Associations For Neuroblastoma

13. MARKETED DRUGS

13.1. UNITUXIN: UNITED THERAPEUTICS CORP
  13.1.1. Drug Description
  13.1.2. Mechanism of Action
  13.1.3. Regulatory Milestones
  13.1.4. Safety and Efficacy
  13.1.5. Product Profile
  13.1.6. Side-Effects
13.2. QARZIBA: EUSA PHARMA
  13.2.1. Drug Description
  13.2.2. Mechanism of Action
  13.2.3. Regulatory Milestones
  13.2.4. Safety and Efficacy
  13.2.5. Product Profile
  13.2.6. Side-Effects

14. KEY-CROSS COMPETITION

15. PIPELINE PROFILES

15.1. NAXITAMAB: Y-MABS THERAPEUTICS INC
  15.1.1. Regulatory Milestones
  15.1.2. Other Development Activities
  15.1.3. Clinical Development
  15.1.4. Clinical Trials Information
  15.1.5. Product Profile
15.2. OMBURTAMAB: Y-MABS THERAPEUTICS INC
  15.2.1. Regulatory Milestones
  15.2.2. Other development activities
  15.2.3. Clinical Development
  15.2.4. Clinical Trials Information
  15.2.5. Safety and Efficacy
  15.2.6. Product Profile
15.3. BEVACIZUMAB + IRINOTECAN +TEMOZOLOMIDE: GENENTECH, INC
  15.3.1. Clinical Development
  15.3.2. Clinical Trials Information
  15.3.3. Safety and Efficacy
  15.3.4. Product Profile
15.4. MNX-100: METRONOMX
  15.4.1. Other Development Activities
  15.4.2. Clinical Development
  15.4.3. Clinical Trials Information
  15.4.4. Safety and Efficacy
  15.4.5. Product Profile
15.5. CPP-1X: CANCER PREVENTION PHARMACEUTICALS
  15.5.1. Regulatory Milestones
  15.5.2. Other Development Activities
  15.5.3. Clinical Development
  15.5.4. Clinical Trials Information
  15.5.5. Product Profile

16. NEUROBLASTOMA: MARKET ANALYSIS

16.1. Key Findings
16.2. Market Outlook: 7 Major Markets
16.3. Market Size Of Neuroblastoma In 7mm (2016-2028)
16.4. Risk Group Wise Market Size Of Neuroblastoma in 7MM (2016-2028)
16.5. Therapy Wise Market Size Of Neuroblastoma In 7MM (2016-2028)
16.6. NEUROBLASTOMA: US MARKET OUTLOOK
  16.6.1. US Market Size
  16.6.2. Risk Group wise Market Size
  16.6.3. Therapy wise Market size
16.7. NEUROBLASTOMA: EU5 MARKET OUTLOOK
16.8. GERMANY MARKET SIZE
  16.8.1. Risk Group wise Market Size
  16.8.2. Therapy wise Market size
16.9. FRANCE MARKET SIZE
  16.9.1. Risk Group wise Market Size
  16.9.2. Therapy wise Market size
16.10. UNITED KINGDOM MARKET SIZE
  16.10.1. Risk Group wise Market Size
  16.10.2. Therapy wise Market size
16.11. SPAIN MARKET SIZE
  16.11.1. Risk Group wise Market Size
  16.11.2. Therapy wise Market size
16.12. ITALY MARKET SIZE
  16.12.1. Risk Group wise Market Size
  16.12.2. Therapy wise Market size
16.13. NEUROBLASTOMA: JAPAN MARKET OUTLOOK
  16.13.1. JAPAN MARKET SIZE
  16.13.2. Risk Group wise Market Size
  16.13.3. Therapy wise Market size

17. MARKET DRIVERS

18. MARKET BARRIERS

19. APPENDIX

20. REPORT METHODOLOGY

20.1. Sources used

21. DELVEINSIGHT CAPABILITIES

22. DISCLAIMER

23. ABOUT DELVEINSIGHT

List Of Tables

LIST OF TABLES

TABLE 1: TOTAL INCIDENT PATIENT POPULATION OF NEUROBLASTOMA IN THE 7MM (2016-2028)
TABLE 2: TOTAL INCIDENT PATIENT POPULATION OF NEUROBLASTOMA IN THE UNITED STATES (2016-2028)
TABLE 3: INCIDENT PATIENT POPULATION OF NEUROBLASTOMA BY RISK GROUPS IN THE UNITED STATES (2016-2028)
TABLE 4: TOTAL INCIDENT PATIENT POPULATION OF NEUROBLASTOMA IN GERMANY (2016-2028)
TABLE 5: INCIDENT PATIENT POPULATION OF NEUROBLASTOMA BY RISK GROUPS IN GERMANY (2016-2028)
TABLE 6: TOTAL INCIDENT PATIENT POPULATION OF NEUROBLASTOMA IN FRANCE (2016-2028)
TABLE 7: INCIDENT PATIENT POPULATION OF NEUROBLASTOMA BY RISK GROUPS IN FRANCE (2016-2028)
TABLE 8: TOTAL INCIDENT PATIENT POPULATION OF NEUROBLASTOMA IN THE UNITED KINGDOM (2016-2028)
TABLE 9: INCIDENT PATIENT POPULATION OF NEUROBLASTOMA BY RISK GROUPS IN THE UNITED KINGDOM (2016-2028)
TABLE 10: TOTAL INCIDENT PATIENT POPULATION OF NEUROBLASTOMA IN SPAIN (2016-2028)
TABLE 11: INCIDENT PATIENT POPULATION OF NEUROBLASTOMA BY RISK GROUPS IN SPAIN (2016-2028)
TABLE 12: TOTAL INCIDENT PATIENT POPULATION OF NEUROBLASTOMA IN ITALY (2016-2028)
TABLE 13: INCIDENT PATIENT POPULATION OF NEUROBLASTOMA BY RISK GROUPS IN ITALY (2016-2028)
TABLE 14: TOTAL INCIDENT PATIENT POPULATION OF NEUROBLASTOMA IN JAPAN (2016-2028)
TABLE 15: INCIDENT PATIENT POPULATION OF NEUROBLASTOMA BY RISK GROUPS IN JAPAN (2016-2028)
TABLE 16: KEY-CROSS COMPARISION OF POTENTIAL THERAPIES
TABLE 17: POTENTIAL THERAPIES : SAFETY AND EFFICACY
TABLE 18: NAXITAMAB CLINICAL TRIAL DESCRIPTION, 2016
TABLE 19: OMBURTAMAB, CLINICAL TRIAL DESCRIPTION, 2016
TABLE 20: OMBURTAMAB : SAFETY AND EFFICACY
TABLE 21: (BEVACIZUMAB+ IRINOTECAN +TEMOZOLOMIDE), CLINICAL TRIAL DESCRIPTION, 2016
TABLE 22: (BEVACIZUMAB+ IRINOTECAN +TEMOZOLOMIDE) : SAFETY AND EFFICACY
TABLE 23: MNX-100,CLINICAL TRIAL DESCRIPTION, 2016
TABLE 24: MNX-100: SAFETY AND EFFICACY
TABLE 25: CPP-1X,CLINICAL TRIAL DESCRIPTION, 2016
TABLE 26: 7 MAJOR MARKET SIZE OF NEUROBLASTOMA IN USD MILLION (2016-2028)
TABLE 27: RISK GROUP WISE MARKET SIZE OF NEUROBLASTOMA IN THE 7MM (2016-2028)
TABLE 28: THERAPY WISE MARKET SIZE OF NEUROBLASTOMA IN THE 7MM (2016-2028)
TABLE 29: MARKET SIZE OF NEUROBLASTOMA IN THE UNITED STATES, USD MILLIONS (2016-2028)
TABLE 30: RISK GROUP WISE MARKET SIZE OF NEUROBLASTOMA IN THE UNITED STATES, USD MILLIONS (2016-2028)
TABLE 31: THERAPY-WISE MARKET SIZE OF NEUROBLASTOMA IN UNITED STATES, USD MILLIONS (2016-2028)
TABLE 32: MARKET SIZE OF NEUROBLASTOMA IN GERMANY, USD MILLIONS (2016-2028)
TABLE 33: RISK GROUP WISE MARKET SIZE OF NEUROBLASTOMA IN GERMANY, USD MILLIONS (2016-2028)
TABLE 34: THERAPY-WISE MARKET SIZE OF NEUROBLASTOMA IN GERMANY, USD MILLIONS (2016-2028)
TABLE 35: MARKET SIZE OF NEUROBLASTOMA IN FRANCE, USD MILLIONS (2016-2028)
TABLE 36: RISK GROUP WISE MARKET SIZE OF NEUROBLASTOMA IN FRANCE, USD MILLIONS (2016-2028)
TABLE 37: THERAPY-WISE MARKET SIZE OF NEUROBLASTOMA IN FRANCE, USD MILLIONS (2016-2028)
TABLE 38: MARKET SIZE OF NEUROBLASTOMA IN THE UNITED KINGDOM, USD MILLIONS (2016-2028)
TABLE 39: RISK GROUP WISE MARKET SIZE OF NEUROBLASTOMA IN THE UNITED KINGDOM, USD MILLIONS (2016-2028)
TABLE 40: THERAPY-WISE MARKET SIZE OF NEUROBLASTOMA IN THE UNITED KINGDOM, USD MILLIONS (2016-2028)
TABLE 41: MARKET SIZE OF NEUROBLASTOMA IN SPAIN, USD MILLIONS (2016-2028)
TABLE 42: RISK GROUP WISE MARKET SIZE OF NEUROBLASTOMA IN SPAIN, USD MILLIONS (2016-2028)
TABLE 43: THERAPY-WISE MARKET SIZE OF NEUROBLASTOMA IN SPAIN, USD MILLIONS (2016-2028)
TABLE 44: MARKET SIZE OF NEUROBLASTOMA IN ITALY, USD MILLIONS (2016-2028)
TABLE 45: RISK GROUP WISE MARKET SIZE OF NEUROBLASTOMA IN ITALY, USD MILLIONS (2016-2028)
TABLE 46: THERAPY-WISE MARKET SIZE OF NEUROBLASTOMA IN ITALY, USD MILLIONS (2016-2028)
TABLE 47: MARKET SIZE OF NEUROBLASTOMA IN JAPAN, USD MILLIONS (2016-2028)
TABLE 48: RISK GROUP WISE MARKET SIZE OF NEUROBLASTOMA IN JAPAN, USD MILLIONS (2016-2028)
TABLE 49: THERAPY-WISE MARKET SIZE OF NEUROBLASTOMA IN JAPAN, USD MILLIONS (2016-2028)

List Of Figures

LIST OF FIGURES

FIGURE 1: STAGING OF NEUROBLASTOMA
FIGURE 2: SIGNS AND SYMPTOMS OF NEUROBLASTOMA
FIGURE 3: PATHOGENESIS OF NEUROBLASTOMA
FIGURE 4: THERAPEUTIC TARGETS FOR NEUROBLASTOMA
FIGURE 5: INITIAL DIAGNOSTIC WORK FOR NEUROBLASTOMA
FIGURE 6: TOTAL INCIDENT PATIENT POPULATION OF NEUROBLASTOMA IN THE 7MM (2016-2028)
FIGURE 7: TOTAL INCIDENT PATIENT POPULATION OF NEUROBLASTOMA IN THE UNITED STATES (2016-2028)
FIGURE 8: INCIDENT PATIENT POPULATION OF NEUROBLASTOMA BY RISK GROUPS IN THE UNITED STATES (2016-2028)
FIGURE 9: TOTAL INCIDENT PATIENT POPULATION OF NEUROBLASTOMA IN GERMANY (2016-2028)
FIGURE 10: INCIDENT PATIENT POPULATION OF NEUROBLASTOMA BY RISK GROUPS IN GERMANY (2016-2028)
FIGURE 11: TOTAL INCIDENT PATIENT POPULATION OF NEUROBLASTOMA IN FRANCE (2016-2028)
FIGURE 12: INCIDENT PATIENT POPULATION OF NEUROBLASTOMA BY RISK GROUPS IN FRANCE (2016-2028)
FIGURE 13: TOTAL INCIDENT PATIENT POPULATION OF NEUROBLASTOMA IN THE UNITED KINGDOM (2016-2028)
FIGURE 14: INCIDENT PATIENT POPULATION OF NEUROBLASTOMA BY RISK GROUPS IN THE UNITED KINGDOM (2016-2028)
FIGURE 15: TOTAL INCIDENT PATIENT POPULATION OF NEUROBLASTOMA IN SPAIN (2016-2028)
FIGURE 16: INCIDENT PATIENT POPULATION OF NEUROBLASTOMA BY RISK GROUPS IN SPAIN (2016-2028)
FIGURE 17: TOTAL INCIDENT PATIENT POPULATION OF NEUROBLASTOMA IN ITALY (2016-2028)
FIGURE 18: INCIDENT PATIENT POPULATION OF NEUROBLASTOMA BY RISK GROUPS IN ITALY (2016-2028)
FIGURE 19: TOTAL INCIDENT PATIENT POPULATION OF NEUROBLASTOMA IN JAPAN (2016-2028)
FIGURE 20: INCIDENT PATIENT POPULATION OF NEUROBLASTOMA BY RISK GROUPS IN JAPAN (2016-2028)
FIGURE 21: GENERAL TREATMENT OF NEUROBLASTOMA
FIGURE 22: TREATMENT ALGORITHM OF NEUROBLASTOMA
FIGURE 23: RISK STRATIFICATION OF NEUROBLASTOMA
FIGURE 24: TREATMENT ALGORITHM OF NEUROBLASTOMA
FIGURE 25: TOTAL MARKET SIZE OF NEUROBLASTOMA IN THE 7MM (2016-2028)
FIGURE 26: RISK GROUP WISE MARKET SIZE OF NEUROBLASTOMA IN THE 7MM (2016-2028)
FIGURE 27: THERAPY WISE MARKET SIZE OF NEUROBLASTOMA IN THE 7MM (2016-2028)
FIGURE 28: MARKET SIZE OF NEUROBLASTOMA IN THE UNITED STATES, USD MILLIONS (2016-2028)
FIGURE 29: RISK GROUP WISE MARKET SIZE OF NEUROBLASTOMA IN THE UNITED STATES, USD MILLIONS (2016-2028)
FIGURE 30: THERAPY-WISE MARKET SIZE OF NEUROBLASTOMA IN UNITED STATES, USD MILLIONS (2016-2028)
FIGURE 31: MARKET SIZE OF NEUROBLASTOMA IN GERMANY, USD MILLIONS (2016-2028)
FIGURE 32: RISK GROUP WISE MARKET SIZE OF NEUROBLASTOMA IN GERMANY, USD MILLIONS (2016-2028)
FIGURE 33: THERAPY-WISE MARKET SIZE OF NEUROBLASTOMA IN GERMANY, USD MILLIONS (2016-2028)
FIGURE 34: MARKET SIZE OF NEUROBLASTOMA IN FRANCE, USD MILLIONS (2016-2028)
FIGURE 35: RISK GROUP WISE MARKET SIZE OF NEUROBLASTOMA IN FRANCE, USD MILLIONS (2016-2028)
FIGURE 36: THERAPY-WISE MARKET SIZE OF NEUROBLASTOMA IN FRANCE, USD MILLIONS (2016-2028)
FIGURE 37: MARKET SIZE OF NEUROBLASTOMA IN THE UNITED KINGDOM, USD MILLIONS (2016-2028)
FIGURE 38: RISK GROUP WISE MARKET SIZE OF NEUROBLASTOMA IN THE UNITED KINGDOM, USD MILLIONS (2016-2028)
FIGURE 39: THERAPY-WISE MARKET SIZE OF NEUROBLASTOMA IN THE UNITED KINGDOM, USD MILLIONS (2016-2028)
FIGURE 40: MARKET SIZE OF NEUROBLASTOMA IN SPAIN, USD MILLIONS (2016-2028)
FIGURE 41: RISK GROUP WISE MARKET SIZE OF NEUROBLASTOMA IN SPAIN, USD MILLIONS (2016-2028)
FIGURE 42: THERAPY-WISE MARKET SIZE OF NEUROBLASTOMA IN SPAIN, USD MILLIONS (2016-2028)
FIGURE 43: MARKET SIZE OF NEUROBLASTOMA IN ITALY, USD MILLIONS (2016-2028)
FIGURE 44: RISK GROUP WISE MARKET SIZE OF NEUROBLASTOMA IN ITALY, USD MILLIONS (2016-2028)
FIGURE 45: THERAPY-WISE MARKET SIZE OF NEUROBLASTOMA IN ITALY, USD MILLIONS (2016-2028)
FIGURE 46: MARKET SIZE OF NEUROBLASTOMA IN JAPAN, USD MILLIONS (2016-2028)
FIGURE 47: RISK GROUP WISE MARKET SIZE OF NEUROBLASTOMA IN JAPAN, USD MILLIONS (2016-2028)
FIGURE 48: THERAPY-WISE MARKET SIZE OF NEUROBLASTOMA IN JAPAN, USD MILLIONS (2016-2028)
FIGURE 49: MARKET DRIVERS
FIGURE 50: MARKET BARRIERS